Kazia Therapeutics Files 6-K, Formerly Novogen Ltd
Ticker: KZIA · Form: 6-K · Filed: May 15, 2025 · CIK: 1075880
Sentiment: neutral
Topics: reporting, corporate-info
TL;DR
Kazia Therapeutics (fka Novogen) filed a 6-K on 5/15/25, confirming its Sydney HQ.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on May 15, 2025, reporting information as a foreign private issuer. The filing details the company's principal executive office located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000. Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a name change occurring on December 28, 1998.
Why It Matters
This filing provides an update on Kazia Therapeutics' status as a foreign private issuer and confirms its corporate identity and address, which is standard for ongoing reporting requirements.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain new material financial or operational information that would typically increase risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- May 15, 2025 (date) — Filing date
- Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000 (location) — Principal executive office address
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer to the U.S. Securities and Exchange Commission.
When was Kazia Therapeutics Limited formerly known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd.
On what date did the company change its name from Novogen Ltd?
The company changed its name from Novogen Ltd on December 28, 1998.
Where is Kazia Therapeutics Limited's principal executive office located?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics file its annual reports under Form 20-F or Form 40-F?
Kazia Therapeutics files its annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 15, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).